In recent trading session, iBio, Inc. (NYSE:IBIO) saw 1,974,416 shares changing hands with its beta currently measuring -6.09. Company’s recent per share price level of $2.05 trading at -$0.03 or -1.44% at recent trade assigns it a market valuation of $369.59 Million. That current trading price of IBIO’s stock is at a discount of -263.42% from its 52-week high price of $7.45 and is indicating a premium of 97.56% from its 52-week low price of $0.05. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 7.31 Million shares which gives us an average trading volume of 29.58 Million if we extend that period to 3-months.

For iBio, Inc. (IBIO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2. Splitting up the data highlights that, out of 1 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 1 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.07 in the current quarter.

iBio, Inc. (NYSE:IBIO) trade information

In the face of being in the red today for losing -1.44%, in the last five days IBIO remained trading in the green while hitting it’s week-highest on Tuesday, Oct 13 when the stock touched $2.28-9 price level, adding 9.6% to its value on the day. iBio, Inc.’s shares saw a change of 727.75% in year-to-date performance and have moved 0.54% in past 5-day. iBio, Inc. (NYSE:IBIO) showed a performance of -4.13% in past 30-days. Number of shares sold short was 16.41 Million shares which calculate 0.55 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $3.1 to the stock, which implies a rise of 51.22% to its current value. Analysts have been projecting $3.1 as a low price target for the stock while placing it at a high target of $3.1. It follows that stock’s current price would jump +51.22% in reaching the projected high whereas dropping to the targeted low would mean a loss of 51.22% for stock’s current value.

iBio, Inc. (IBIO) estimates and forecasts

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -10.1% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 38.7% while estimates for its earnings growth in next 5 years are of 0%